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Stereotactic radiotherapy for early stage non-small  
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Umberto Ricardi, MD, Serena Badellino, MD, Andrea Riccardo Filippi, MD
Department of Oncology, Radiation Oncology, University of Torino, Torino, Italy
Stereotactic body radiotherapy (SBRT) represents a consolidated treatment option for patients with medically inoperable early 
stage non-small cell lung cancer (NSCLC). The clinical evidence accumulated in the past decade supports its use as an alternative 
to surgery with comparable survival outcomes. Due to its limited toxicity, SBRT is also applicable to elderly patients with very poor 
baseline pulmonary function or other severe comorbidities. Recent comparative studies in operable patients raised the issue of the 
possible use of SBRT also for this subgroup, with quite promising results that still should be fully confirmed by prospective trials 
with long-term follow-up. Aim of this review is to summarize and discuss the major studies conducted over the years on SBRT 
and to provide data on the efficacy and toxicity of this radiotherapy technique for stage I NSCLC. Technical aspects and quality of 
life related issues are also discussed, with the goal to provide information on the current role and limitations of SBRT in clinical 
practice.
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Introduction
The treatment of choice for early-stage non-small cell lung 
cancer (NSCLC) is anatomical surgical resection. However, 
a growing number of patients are considered medically or 
functionally not amenable with surgery, also as a consequence 
of the progressively increasing age of the general population. 
In the past, a consistent proportion of these patients were not 
offered any kind of treatment or, in alternative, they underwent 
conventionally fractionated radiotherapy (RT), although with a 
considerably worse outcome if compared to surgical resection 
[1]. For stage I NSCLC, surgery is able to obtain survival 
projections at 12 years ranging between 69% (for tumors 
with a maximum diameter of 5–15 mm), and 43% (for larger 
tumors, with maximum diameter >45 mm). Conventional 
external beam radiotherapy is associated to 5-year overall 
survival (OS) rate of only 15%, with local failure rates ranging 
from 30% to 70% [2]. In the mid-1990s, at Karolinska Hospital 
in Sweden, researchers firstly transferred the principles of 
cranial stereotactic radiosurgery to extra-cranial tumor 
sites, especially lung [3]. This so-called stereotactic body 
radiotherapy (SBRT) approach, also known as stereotactic 
ablative radiotherapy (SABR), was then further developed by 
several centers worldwide [4-6]. SBRT is currently defined as 
a technique for delivering external beam radiotherapy with 
a high degree of accuracy to an extra-cranial target, using 
high doses per fraction, in 1–8 treatment fractions [7]. In the 
SBRT technique, specialized treatment planning results in high 
radiation dose with a steep dose gradient beyond the target; 
the challenge is to hit the entire extent of the tumor with an 
extremely efficient and biologically damaging therapy, while 
simultaneously avoiding the surrounding normal tissues (local 
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tumor control rates of 90% and higher, with rates of severe 
toxicity below 10%).
SBRT for Medically Inoperable Non-Small 
Cell Lung Cancer
National Comprehensive Cancer Network Guidelines as well 
as the European Society of Medical Oncology (ESMO) Clinical 
Practice Guidelines now consider SBRT as the first line 
treatment option for medically inoperable patients affected 
with stage I NSCLC [7]. SBRT is an attractive alternative 
therapy for several reasons: outpatient, non-invasive, 20–30 
minutes per treatment, short overall treatment time (1–2 
weeks), no sedation or anesthesia (painless), immediate return 
to activities.
Population-based analyses from the Netherlands [8,9] and 
the United States [10] demonstrated an improvement in OS for 
stage I NSCLC in elderly patients following the introduction 
of SBRT in clinical practice. Haasbeek et al. [8] showed that 
for patients treated with radiotherapy OS was improved from 
16 months to 24 months between 2001 and 2009 in the 
Netherlands. According to the data collected in the Amsterdam 
Cancer Registry, Palma et al. [9] demonstrated changes in 
treatment and survival in elderly patients with stage I NSCLC 
after the introduction of SBRT; in particular, a 16% absolute 
increase in RT use, a decline of 12% in the proportion of 
untreated elderly patients, and an improvement in OS.
Shirvani et al. [10] compared the effectiveness of lobectomy, 
sublobar resection, conventional radiotherapy, SBRT, and 
observation in patients older than 65 years, based on 
Surveillance Epidemiology and End Results (SEER) program. In 
this study, OS was significantly improved with SBRT and was 
similar to that after lobectomy.
Moreover, Hayashi et al. [11] retrospectively analyzed the 
clinical outcomes and feasibility in a series of 20 very elderly 
patients (age ≥85 years) with stage I NSCLC and 61 younger 
patients (age <85 years), demonstrating no differences in 
tumor control according to age, although very elderly patients 
experienced more frequently severe radiation pneumonitis (G3 
pneumonitis in 10% and 0%, respectively).
A part from retrospective, observational and registry studies, 
as shown in Table 1 several research groups have reported 
phase I and II trials of SBRT for early-stage NSCLC [6,12-
17]. Total doses ranged from 45 to 66 Gy delivered in 3 or 4 
fractions, with 2–3 years local tumor control rates and 1–3 
years OS projections ranging between 84%–98% and 43%–
72%, respectively. Timmerman et al. [6] and McGarry et al. [12] 
enrolled 47 patients between 2000 and 2003 in one of the first 
phase I studies to evaluate the safety of SBRT in clinical stage 
T1 or T2 tumors, lymph node negative, medically inoperable 
NSCLC [13]. The initial dose was 24 Gy over 3 fractions, then 
escalated by 2 Gy per fraction increments up to the total 
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dose of 60 Gy. With 60% of partial response rate and 27% of 
complete response rate, mean tolerated dose was not reached 
for T1 tumors, though for tumors >5 cm, the mean tolerated 
dose was determined to be 66 Gy. In the United States, 
preliminary interesting findings from the University of Indiana 
led to the design of the Radiation Therapy Oncology Group 
(RTOG) 0236 trial, a phase II study in which 55 patients were 
enrolled and all received 60 Gy in 3 fractions for peripherally 
located tumors. Results demonstrated a 3-year actuarial local 
control (LC) rate of 98%, with OS at 3 years of 56% (median 
OS of 4 years) [15].
As better local tumor control was shown to go along with 
higher OS in patients treated with conventional radiation 
therapy [18], it can also be expected that improvements 
in local control and survival can be achievable by applying 
higher SBRT doses [10]. To help better define the dose and 
fractionation required for tumor sterilization with SBRT, 
various studies examined the biologically effective dose (BED) 
delivered to the tumor. In a Japanese multi-institutional 
retrospective review of 245 patients treated with a variety of 
dose and fractionation schedules, Onishi et al. [19] concluded 
that local control was significantly improved with BED greater 
than 100 Gy (prescription dose at isocenter), with 5-year LC 
rate of 84% for BED10 > 100 Gy vs. 37% for BED10 < 100 Gy (p 
< 0.001). More recently, Kestin et al. [20] found a significant 
correlation between BED10 > 105 Gy (prescription to the 
edge of the PTV, with 60%–90% of the isocenter dose) and 
higher local control. A meta-analysis done by Zhang et al. [21] 
evaluated the optimal BED by analyzing 34 previously reported 
studies. After dividing the studies into subgroups based on 
the BED quartiles (low, medium, medium–high, and high), they 
showed that the outcome got worse for BED below 83.2 Gy 
and for BED exceeding 146 Gy. In 2015, researchers from the 
University of Illinois at Chicago, examined different SBRT dose 
schedules using the National Cancer Database and found that 
patients with T2 tumors treated with a BED10 > 150 Gy (roughly 
equal to 54 Gy in 3 fractions) had a significantly improved 
survival compared with patients treated with a BED10 < 150 
Gy [22]. Nowadays, the current recommended dose for SBRT 
is a minimum of 100 Gy BED, prescribed to the target volume 
encompassing isodose, typically delivered in one to eight 
fractions.
As fatal toxicities were previously reported when treating 
central tumors (in close proximity of critical structures such as 
main bronchi, trachea and big vessels) [23], subsequent studies 
showed that the use of ‘risk-adapted’ fractionation schemes 
delivering the minimal required dose of 100 Gy BED in a larger 
number of fractions were able to obtain satisfactory tumor 
control rates with an acceptable toxicity [24].
Large retrospective observational studies confirmed the 
good results described above in clinical practice. The working 
group ‘Extra-cranial Stereotactic Radiotherapy’ of the 
German Society for Radiation Oncology (DEGRO) conducted 
a multicenter study on patterns of care and outcome analysis 
on a cohort of 582 patients treated with SBRT in Germany and 
Austria between 1998 and 2011. In this study, dose escalation 
(BED of at least 106 Gy) emerged as significant factor 
influencing OS and LC, while stage IA was correlated with a 
better OS, with only a trend for a better LC [25]. Similarly, in a 
cohort of 196 patients with histological/cytological diagnosis 
of NSCLC treated with SBRT included in an Italian multicenter 
observational study, stage IA was correlated with better OS 
and cancer-specific survival (CSS) [26].
The pattern of relapse following SBRT is characterized by a 
predominant failure at distant sites, with a significant impact 
on OS (together with non-cancer deaths secondary to other 
comorbidities typical of an elderly non-surgical population). 
The probability of distant metastases is up to 20%–26% of 
cases and is related to tumor size [25-28]. 
Despite the difficulties in conducting randomized clinical 
trials (RCTs) comparing SBRT with surgery or conventional 
radiotherapy, at the European Society for Radiotherapy and 
Oncology (ESTRO) 2014 meeting, the results of the SPACE trial 
were presented in abstract form [29]. This trial randomized 
102 patients to SBRT (66 Gy in 3 fractions and 45 Gy at 
the periphery) or conventional radiotherapy (70 Gy in 35 
fractions); with a limited follow-up, local control did not differ 
between the two arms, but the conventional treatment was 
associated with a higher risk of grade 1–2 toxicity (esophagitis 
and pneumonitis). Accrual to a similarly designed RCT (CHISEL, 
Clinicaltrials.gov NCT01014130) is ongoing; however, unlike 
SPACE, CHISEL employs smaller margins and cone beam 
computed tomography (CT) setup in the conventional RT arm.
SBRT for Medically Operable Patients
Standard therapy for operable, clinical stage I, NSCLC is 
lobectomy with mediastinal lymph nodes sampling [30]. Today, 
sublobar anatomical resection (segmentectomy) is discussed as 
another possible option [31], but comparative studies between 
segmentectomy and lobectomy are still ongoing [32].
As summarized in Table 2, findings from population-based 
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studies and propensity score matched analyses suggest that 
overall survival and disease-specific survival after SBRT are 
similar to those after surgery [33-37]. However, concerns 
remain about the risk of local or nodal recurrence after 
SBRT, either of which could lead to worse OS. Grills et al. 
[33] performed a retrospective single-institution comparison 
between SBRT and wedge resection, showing improved local 
tumor control in favor of SBRT (5% vs. 24%), no differences 
in CSS and a superior OS projection for the surgical cohort 
(older age and increased comorbidities in the SBRT patients). 
Crabtree et al. [34] analyzed 257 patients, again with the 
propensity score method, and demonstrated no difference 
between local recurrence, CSS or OS after 3 years between 
SBRT and surgery. Verstegen et al. [35] compared SBRT and 
video-assisted thoracoscopic surgery (VATS) lobectomy in 128 
patients after matching for patients’ characteristics (as gender, 
age, performance status, clinical tumor stage, location of the 
tumor, tumor histology, forced expiratory volume in the first 
second [FEV1], and Charlson comorbidity index). Locoregional 
control resulted to be better after SBRT, with no differences 
in freedom from progression and OS. The previously cited 
US population-based SEER analysis found no difference in 
OS and CSS for SBRT versus sublobar resection or lobectomy 
after propensity score matching [36]. Recently, Mokhles et al. 
[37] selected 577 patients (96 who undergone VATS or open 
lobectomy at Erasmus University Medical Center of Rotterdam 
and 481 treated with SBRT at Vrije University Medical Center 
in Amsterdam) and matched two cohorts of 73 patients in 
each group, according to propensity score method. OS rates 
at 12 and 60 months were 95% and 80% in surgery group, 
and 94% and 53% in SBRT group, respectively (p = 0.089). This 
trend towards an improved survival after 3 years in surgically 
treated patients could be explained by the pathological lymph 
node staging (selection of patients requiring adjuvant therapy), 
and by differences between the two groups, as the matching 
was done with only a limited number of variables (i.e., staging 
procedure was not included as a covariate). Long-term follow-
up SBRT studies are needed to fully confirm this finding.
Few studies (with limited numbers of patients) reported 
the outcomes after SBRT in patients who refused surgery, 
reporting 3- and 5-year OS rates higher than 80% and 70%, 
respectively [38,39]. 
Three phase III randomized studies have been initiated to 
compare SBRT with surgery in patients with early-stage NSCLC 
(the STARS trial [NCT00840749], the ROSEL trial [NCT00687986], 
and the ACOSOG Z4099 trial [NCT01336894]), but they were all 
closed earlier because of the slow accrual.
In May 2015, a pooled analysis of the data from STARS and 
Table 2. Studies comparing surgery and SBRT in stage I NSCLC
Author (yr) Study design No. of patients Surgical procedure
Overall survival
Surgery SBRT










































































Lobectomy vs. SBRT, 
HR 1.01 (SA: 1.16–1.28)
 
 
























SBRT, stereotactic body radiotherapy; NSCLC, non-small cell lung cancer; VATS, video-assisted thoracoscopic surgery; HR, hazard ratio; 
SA, sensitivity analyses; SEER, Surveillance Epidemiology and End Results.
61
Radiotherapy for stage I NSCLC
www.e-roj.orghttp://dx.doi.org/10.3857/roj.2015.33.2.57
ROSEL trials (that had similar entry criteria) has been published 
[40]. Overall, 58 patients were enrolled and randomly assigned 
(31 to SABR and 27 to surgery); with a median follow-up of 
40.2 months for the SBRT group and 35.4 months for the 
surgery group, OS at 3 years was 95% and 79% (HR, 0.14), 
respectively. Three patients (10%) in the radiotherapy group 
had grade 3 treatment-related adverse events, with no grade 4 
or treatment-related deaths. In the surgery group, one patient 
(4%) died of surgical complications and 12 patients (44%) had 
grade 3–4 treatment-related adverse events. 
Toxicity and Quality of Life
Radiation pneumonitis (RP) is one of the most common 
toxicities after SBRT, as well as after conventional radiotherapy 
to the lung. Most of the RP is of grade 1 or 2 and either 
asymptomatic or manageable, but in few cases may be severe 
and symptomatic. In large retrospective studies, the incidence 
of grade ≥2 RP was below 8% [25,41]; a higher incidence of 
severe RP has been reported only in patients with pre-existent 
idiopathic pulmonary fibrosis [42]. 
SBRT may be safely delivered in patients with severe 
pulmonary comorbidities and in patients with very poor 
pre-treatment pulmonary function. Previous retrospective 
studies analyzed changes in pulmonary function test (PFT) 
following SBRT, with variable follow-up intervals: most of 
them were limited to spirometric parameters and diffusing 
capacity for carbon monoxide (diffusion capacity of lung for 
carbon monoxide [DLCO]). Guckenberger et al. [43] reported 
that there was no association between pre-treatment PFT 
values and the incidence of RP in patients with severe chronic 
obstructive pulmonary disease (COPD) globally initiative for 
chronic obstructive lung disease (GOLD) stage III–IV, with a 
loss of <10% (FEV1, DLCO) within 24 months after treatment. 
Recently, a more comprehensive analysis of ‘complete’ PFTs 
(including blood gas analysis) was reported, on a series of 
patients enrolled in the RTOG 0236 phase II trial [44]. In this 
report, including the data of 55 patients followed over a 
2-year interval, the mean percentage in FEV1 and DLCO decline 
were 5.8% and 6.3%, respectively, with minimal changes in 
blood gases and no significant decline in oxygen saturation. 
The authors concluded that no clinically significant changes in 
pulmonary function were evident after SBRT, at a dose of 54 
Gy in 3 fractions.
The few studies describing quality-of-life (QoL) after SBRT 
have limited follow-up and analyzed patients less fit at 
baseline, reporting that SBRT had no detrimental or negative 
on QoL. In general, overall QoL as well as the subdomains of 
dyspnea and cough, was stable after SBRT [45].
Rib fractures and neuralgia have been reported in few 
patients, when tumor was close to chest wall. Severe toxicity 
to the brachial plexus (neuropathic pain, motor weakness, or 
sensory alteration), large bronchi (stenosis with pulmonary 
atelectasis), and esophagus (ulceration, perforation, fistula) 
has been reported but these events are uncommon.
There have been few studies on CT findings after SBRT 
for lung cancer, describing two stages: early acute RP that 
occurs within 6 months of treatment and radiation fibrosis 
that occurs 6 months or more after treatment. CT findings 
after SBRT does not seem to have the same appearance, 
distribution and progression as those following conventional 
radiotherapy; this is due to the difference in dose delivery, 
biologic effects and overall treatment time. In order to provide 
useful evaluation systems of radiological changes after SBRT, 
researchers developed different scales using descriptive 
categories. Acute radiological toxicity was scored using a 
five-point scoring system developed by Vrije University [46], 
modified from Kimura et al. [47] (1, diffuse consolidation; 
2, patchy consolidation; 3, diffuse ‘ground glass opacity’; 4, 
patchy ‘ground glass opacity’; 5, no changes). Late radiological 
toxicity was scored according to the Koenig’s Scale (0, absence 
of changes; 1, modified conventional pattern; 2, mass like 
pattern; 3, scar like pattern) [48]. Radiation-induced lung 
injury can manifest as a CT-density changes in up to 90% of 
cases at 2 years after SBRT. These changes can occasionally 
mimic a tumor recurrence; therefore, it is important to 
recognize some high-risk radiological features on serial CT 
scans that are suggestive of recurrence (i.e., enlarging opacity, 
sequential enlargement, enlargement after 12 months, bulging 
margin, linear margin disappearance, loss air bronchogram, 
and craniocaudal growth) [49].
Technical Aspects
Several professional groups have reported guidelines for 
SBRT, and technological advances together with dedicated 
quality assurance programs have improved the ability of 
radiation oncologists to deliver large hypo-fractionated 
doses. SBRT can be performed using either traditional linear 
accelerators (equipped with image-guidance technology) 
or linear accelerators specifically adapted for SBRT with 
dedicated delivery systems. The SBRT procedure was initially 
defined by the use of stereotactic frame-based patient set-
up. Currently, in many centers a frame-based patient set-up 
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has been replaced by image-guidance (frameless SBRT). With 
frameless patient set-up, external stereotactic coordinates 
are replaced by the visualization of a patient’s anatomy by 
using images acquired on-table and subsequently compared 
with pretreatment planning images. Several technologies for 
image guidance are commercially available, and superiority of 
one method over the other has not been demonstrated. Use 
of volumetric imaging (cone beam CT), as opposed to only 
implanted fiducials, has the advantage of enabling assessment 
of changes in target shape and position, relative to the 
position of organs at risk.
Four-dimensional CT is the recommended technique for 
SBRT simulation, due to its ability to accurately compensate for 
target motion and to define patient’s specific internal margins. 
For planning, all published prospective trials have used three-
dimensional conformal treatment planning, but more recently, 
also intensity-modulated radiation therapy (IMRT) and 
advanced rotational techniques, such as volumetric modulated 
arc therapy (VMAT), have been widely adopted. VMAT is a form 
of IMRT in which the gantry continuously moves around the 
patient with a varying speed and rate of dose delivery. The 
maximal dose rate reachable by some linear accelerators, with 
a flattening filter free technique, is up to four times faster 
than the standard. Fig. 1 illustrated a typical VMAT plan in a 
man of 78 years old, affected by a peripheral NSCLC in stage 
IA (cT1aN0M0). When using IMRT planning, larger volumes of 
normal pulmonary tissue, including contralateral lung, can be 
exposed to low radiation doses (V5); especially when treating 
larger tumors, doses to the contralateral lung may predict for 
the risk of pneumonitis [50]. However, a publication showed no 
difference in the incidence of radiation pneumonitis between 
three-dimensional conformal radiation therapy (3D-CRT) and 
VMAT [47].
Regarding delivery phase and active motion management 
strategies, continuous irradiation in free breathing is 
performed using the internal target volume concept, the mean 
target position concept, or real-time tumor tracking. Non-
continuous irradiation of the tumor in a reproducible position 
is performed using gated beam delivery in predefined phases 
of the breathing cycle.
Conclusions
Approximately 25% of patients affected with stage I NSCLC 
are not eligible for surgery due to medical contraindications. 
For these patients, SBRT is currently considered the best 
alternative option, on the basis of the previously mentioned 
prospective and retrospective studies. Even for centrally 
located tumours and for patients with poor pulmonary 
function, SBRT has been shown to be feasible and efficient. 
Toxicity is generally mild, with most of the patients developing 
late radiological toxicity without a serious impairment of the 
lung function over time. The recently reported retrospective 
studies comparing SBRT versus surgery added important 
information to the evidence accumulated in the first decade 
of SBRT use. Moreover, the prospective comparison between 
SBRT and lobectomy in operable patients obtained by 
merging the ROSEL and the STARS phase III trials suggested 
a substantial equivalence between surgery and radiotherapy, 
with perhaps a better outcome in terms of survival for SBRT 
due to the virtual absence of treatment-related mortality, 
which is higher for lobectomy (both open and video-assisted). 
At the same time, the few retrospective studies that compared 
limited surgery (segmentectomy or wedge resection) vs. SBRT 
were generally in favour of SBRT, with results of difficult 
interpretation. It should be noted that all these retrospective 
comparisons suffer from several intrinsic limitations and 
flaws. The most important are that, albeit the analyses were 
all adjusted for risk factors, biases in patients’ selection could 
not be completely avoided, suggesting an indication but not 
clear evidence in favour of one treatment modality over the 
other. One of the most important issues is the median follow-
up time of the treated cohorts: for SBRT is generally shorter, 
and this may have an impact in evaluating survival projections 
after 3 years, as underlined by one of the cited studies [36] 
where, surprisingly, the survival rates after 3 years were clearly 
superior for surgery.
In conclusion, available evidence suggests that SBRT is 
Fig. 1. Typical dose distribution of volumetric modulated arc 
therapy plan for a peripheral tumor of the right upper lobe 
(fractionation: 54 Gy in 3 fractions, isodose 80%). PTV, planning 
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an efficient and safe therapy for stage I inoperable NSCLC 
patients; being better tolerated than surgery, SBRT might also 
be considered a valid therapeutic option for operable patients. 
In clinical practice, a multidisciplinary approach should be 
implemented with the aim of determining the best treatment 
strategy on an individual basis. In the decision process, 
many factors should be taken into account, like respiratory 
function, tumor’s dimension and location, age, comorbidities 
and patient’s preference, with the goal to offer the proper 
therapeutic choice in terms of efficacy and morbidity.
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